Clinical Trials Search | Clareo Health

Showing 1-2 of 2 trials

WITHDRAWNPhase 3

Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

NCT04882735

Phase 3 efficacy and safety of acoramidis in subjects with symptomatic Transthyretin Amyloid Polyneuropathy (ATTR-PN)

Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

Eidos Therapeutics, a BridgeBio companyStarted Sep 2021

WITHDRAWN

Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)

NCT02713880

International, multicenter, observational, longitudinal study to identify biomarker/s for the development of a new MS-based biomarker for the early and sensitive diagnosis of Transthyretin-Related Familial Amyloidotic Polyneuropathy from blood and number of correctly identified patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy

Transthyretin AmyloidosisTransthyretin-Related (ATTR) Familial Amyloid PolyneuropathyTransthyretin Amyloid Cardiopathy

CENTOGENE GmbH RostockStarted Aug 2018

Rostock, Germany • Mumbai, India

Data from ClinicalTrials.govTerms

Filters

Filters

Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)

Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)